(EXPO) Exponent - NASDAQ
Sector: Industrials | Industry: Engineering & Construction | Exchange: NASDAQ (USA) | Market Cap: 2.747m USD | Total Return: -23.4% in 12m
Avg Turnover: 34.9M
EPS Trend: 75.4%
Qual. Beats: 0
Rev. Trend: 95.3%
Qual. Beats: 3
Warnings
Beneish M-Score -1.37 > -1.5 - likely earnings manipulation
Fakeout Below Avwap Earnings
Tailwinds
No distinct edge detected
Exponent, Inc. (EXPO) is a multidisciplinary science and engineering consulting firm providing technical analysis and regulatory support across global markets. The company operates through two primary segments: Engineering and Other Scientific, and Environmental and Health. Its service portfolio includes biomechanics, data sciences, thermal sciences, and chemical regulation, serving diverse industries such as energy, life sciences, and transportation.
The firm utilizes a specialized business model focused on forensic engineering and high-stakes litigation support, often investigating the root causes of complex technical failures. Unlike general management consultancies, Exponent’s workforce is predominantly composed of PhD-level scientists and licensed engineers, creating a high barrier to entry within the research and consulting services sub-industry.
Reviewing Exponents historical performance on ValueRay can help determine if its niche market position aligns with your portfolio goals.
- Litigation and recall activity volume drives core engineering services revenue
- High-profile product safety failures increase demand for reactive technical consulting
- Utilization rates of specialized scientific consultants dictate quarterly operating margins
- Expansion of proactive safety consulting reduces cyclical dependence on legal disputes
- Recruitment and retention of PhD-level experts impacts long-term capacity and growth
| Net Income: 108.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -1.08 > 1.0 |
| NWC/Revenue: 32.96% < 20% (prev 54.11%; Δ -21.15% < -1%) |
| CFO/TA 0.18 > 3% & CFO 123.5m > Net Income 108.9m |
| Net Debt (-37.5m) to EBITDA (156.0m): -0.24 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.1m) vs 12m ago -2.96% < -2% |
| Gross Margin: 23.80% > 18% (prev 60.19%; Δ -36.39% > 0.5%) |
| Asset Turnover: 83.11% > 50% (prev 73.25%; Δ 9.86% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.29 (Total Current Assets 340.9m - Total Current Liabilities 142.2m) / Total Assets 687.4m |
| B: 0.99 (Retained Earnings 682.0m / Total Assets 687.4m) |
| C: 0.21 (EBIT TTM 150.9m / Avg Total Assets 725.3m) |
| D: 0.97 (Book Value of Equity 338.3m / Total Liabilities 349.0m) |
| Altman-Z'' = 7.55 = AAA |
| DSRI: 1.10 (Receivables 197.3m/166.8m, Revenue 602.8m/559.1m) |
| GMI: 2.53 (GM 60.19% / 23.80%) |
| AQI: 1.22 (AQ_t 0.30 / AQ_t-1 0.24) |
| SGI: 1.08 (Revenue 602.8m / 559.1m) |
| TATA: -0.02 (NI 108.9m - CFO 123.5m) / TA 687.4m) |
| Beneish M = -1.37 (Cap -4..+1) = D |
As of June 15, 2026, the stock is trading at USD 57.08 with a total of 359,178 shares traded.
Over the past week, the price has changed by -4.32%,
over one month by +6.91%,
over three months by -13.99% and
over the past year by -23.37%.
Exponent has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold EXPO.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.7 | 43.1% |
P/E Trailing = 26.4579
P/E Forward = 29.3255
P/S = 4.9837
P/B = 7.9391
P/EG = 2.0325
Revenue TTM = 602.8m USD
EBIT TTM = 150.9m USD
EBITDA TTM = 156.0m USD
Long Term Debt = 74.3m USD (estimated: total debt 81.0m - short term 6.71m)
Short Term Debt = 6.71m USD (from shortTermDebt, last quarter)
Debt = 81.0m USD (from shortLongTermDebtTotal, last quarter) (leases 81.0m already included)
Net Debt = -37.5m USD (calculated: Debt 81.0m - CCE 118.6m)
Enterprise Value = 2.71b USD (2.75b + Debt 81.0m - CCE 118.6m)
Interest Coverage Ratio = unknown (Ebit TTM 150.9m / Interest Expense TTM 0.0)
EV/FCF = 23.89x (Enterprise Value 2.71b / FCF TTM 113.4m)
FCF Yield = 4.19% (FCF TTM 113.4m / Enterprise Value 2.71b)
FCF Margin = 18.81% (FCF TTM 113.4m / Revenue TTM 602.8m)
Net Margin = 18.07% (Net Income TTM 108.9m / Revenue TTM 602.8m)
Gross Margin = 23.80% ((Revenue TTM 602.8m - Cost of Revenue TTM 459.4m) / Revenue TTM)
Gross Margin QoQ = 28.61% (prev 24.32%)
Tobins Q-Ratio = 3.94 (Enterprise Value 2.71b / Total Assets 687.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 81.0m)
Taxrate = 28.28% (42.9m / 151.9m)
NOPAT = 108.2m (EBIT 150.9m * (1 - 28.28%))
Current Ratio = 2.40 (Total Current Assets 340.9m / Total Current Liabilities 142.2m)
Debt / Equity = 0.24 (Debt 81.0m / totalStockholderEquity, last quarter 338.3m)
Debt / EBITDA = -0.24 (Net Debt -37.5m / EBITDA 156.0m)
Debt / FCF = -0.33 (Net Debt -37.5m / FCF TTM 113.4m)
Total Stockholder Equity = 389.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.02% (Net Income 108.9m / Total Assets 687.4m)
RoE = 27.94% (Net Income TTM 108.9m / Total Stockholder Equity 389.8m)
RoCE = 32.51% (EBIT 150.9m / Capital Employed (Equity 389.8m + L.T.Debt 74.3m))
RoIC = 20.75% (NOPAT 108.2m / Invested Capital 521.8m)
WACC = 7.20% (E(2.75b)/V(2.83b) * Re(7.41%) + D(81.0m)/V(2.83b) * Rd(0.0%) * (1-Tc(0.28)))
Discount Rate = 7.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -15.56 | Cagr: -1.15%
[DCF] Terminal Value 73.10% ; FCFF base≈121.7m ; Y1≈106.7m ; Y5≈86.2m
[DCF] Fair Price = 29.30 (EV 1.38b - Net Debt -37.5m = Equity 1.42b / Shares 48.5m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 75.38 | EPS CAGR: 2.59% | SUE: -0.66 | # QB: 0
Revenue Correlation: 95.27 | Revenue CAGR: 5.71% | SUE: 0.96 | # QB: 3
EPS current Quarter (2026-06-30): EPS=0.60 | Chg30d=+0.17% | Revisions=-43% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.64 | Chg30d=+2.92% | Revisions=-43% | Analysts=4
EPS current Year (2026-12-31): EPS=2.47 | Chg30d=+0.76% | Revisions=-14% | GrowthEPS=+19.3% | GrowthRev=+11.3%
EPS next Year (2027-12-31): EPS=2.76 | Chg30d=+1.47% | Revisions=+25% | GrowthEPS=+11.8% | GrowthRev=+8.5%
[Analyst] Revisions Ratio: -43%